Earnings call transcript: Vitrolife Q2 2025 misses EPS forecast, stock dips

Vitrolife AB reported a significant Q2 2025 earnings miss, with EPS of SEK 0.74 falling 33.33% short of forecasts and revenue also missing projections, prompting a 6.68% stock decline. This underperformance was largely attributed to regulatory impacts in the U.S. IVF market causing patient treatment postponements, compounded by currency headwinds and the effect of discontinued EMEA operations. Despite these challenges, the company achieved 3% organic growth in local currencies, driven by strong consumables and genetic services, and remains cautiously optimistic, noting U.S. patients are postponing rather than canceling IVF cycles.

Analysis

Vitrolife AB (VITR) reported a challenging second quarter for 2025, with earnings per share of SEK 0.74 missing consensus forecasts by a significant 33.33% and revenue of SEK 871 million falling 2.07% short of expectations. The negative results, which prompted a 6.68% pre-market stock decline, were primarily driven by external headwinds, including a 7% year-over-year revenue decrease heavily impacted by an 8% currency drag from a strengthening Swedish Krona. Operationally, the key challenge stemmed from the U.S. market, where a significant drop in IVF cycle volumes occurred after a federal executive order led patients to postpone treatments in anticipation of financial support. This temporary demand trough in the Americas, the company's largest region by sales, was partially offset by strong market share gains in genetic services, resulting in 5% organic growth for the segment. The company's consumables business was a notable bright spot, delivering 9% organic growth globally and an exceptional 17% in the EMEA region, indicating successful market share capture from competitors. However, profitability was severely compressed, with the EBITDA margin falling to 27.8% from 34.7% a year prior, attributed to the currency impact, increased selling expenses for U.S. market expansion, and certain one-off administrative costs. The outlook remains mixed, with management expressing confidence in EMEA but caution for APAC due to a slow recovery in China and delayed capital equipment purchases.

Key Decisions for Investors

• Investors should closely monitor for any policy clarification regarding the U.S. IVF executive order, as this represents the primary catalyst for unlocking postponed treatment cycles and reversing the negative sentiment.
• Pay attention to the underlying operational strength, particularly the high-single-digit organic growth in the global consumables business, as this demonstrates market share gains that could accelerate revenue growth once external headwinds subside.
• Given the stock is trading near its 52-week low despite a strong financial health score, consider whether the current valuation adequately prices in the risks of U.S. regulatory uncertainty, a slow APAC recovery, and ongoing currency volatility.
• Scrutinize upcoming reports for evidence of margin stabilization, focusing on the impact of currency movements and whether the elevated operating expenses related to U.S. expansion and one-off legal costs begin to normalize.